Recent antibacterial carbohydrate-based prodrugs, drugs and delivery systems to overcome antimicrobial resistance

IF 6.9 2区生物学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Current Opinion in Chemical Biology Pub Date : 2024-01-13 DOI:10.1016/j.cbpa.2023.102419

Catarina Maria, Ana M. de Matos, Amélia P. Rauter

{"title":"Recent antibacterial carbohydrate-based prodrugs, drugs and delivery systems to overcome antimicrobial resistance","authors":"Catarina Maria, Ana M. de Matos, Amélia P. Rauter","doi":"10.1016/j.cbpa.2023.102419","DOIUrl":null,"url":null,"abstract":"<div><p>Antimicrobial resistance is an increasing phenomenon that is threatening global health. Tuberculosis causative bacteria and several resistant and multidrug-resistant bacteria are widely spread and listed by the World Health Organization as global priorities for research and development. Hence, new antibacterial agents with new modes of action are urgently required. In this context, carbohydrate-based drugs have been extensively studied and used, presenting several benefits for therapeutical purposes. In this review, the latest efforts done in the carbohydrate-based antibacterial agents research field, reported from 2021 to 2023, are summarized. Carbohydrate-based prodrugs, drugs, and delivery systems are covered, highlighting derivatization of existing antibiotics, use of nanotechnology, and repurposing of available therapeutical agents as the most popular strategies used in antibacterial agents’ development.</p></div>","PeriodicalId":291,"journal":{"name":"Current Opinion in Chemical Biology","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1367593123001576/pdfft?md5=8337daa1784f79328d2b00c0681588b1&pid=1-s2.0-S1367593123001576-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Chemical Biology","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1367593123001576","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Antimicrobial resistance is an increasing phenomenon that is threatening global health. Tuberculosis causative bacteria and several resistant and multidrug-resistant bacteria are widely spread and listed by the World Health Organization as global priorities for research and development. Hence, new antibacterial agents with new modes of action are urgently required. In this context, carbohydrate-based drugs have been extensively studied and used, presenting several benefits for therapeutical purposes. In this review, the latest efforts done in the carbohydrate-based antibacterial agents research field, reported from 2021 to 2023, are summarized. Carbohydrate-based prodrugs, drugs, and delivery systems are covered, highlighting derivatization of existing antibiotics, use of nanotechnology, and repurposing of available therapeutical agents as the most popular strategies used in antibacterial agents’ development.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

克服抗菌药耐药性的最新抗菌碳水化合物原药、药物和给药系统

抗菌药耐药性现象日益严重，威胁着全球健康。结核病致病菌和几种耐药性和多重耐药菌广泛传播，并被世界卫生组织列为全球优先研发对象。因此，迫切需要具有新作用模式的新型抗菌剂。在这种情况下，以碳水化合物为基础的药物得到了广泛的研究和应用，在治疗方面具有多种优势。本综述总结了 2021 年至 2023 年碳水化合物类抗菌剂研究领域的最新进展。本综述涵盖了基于碳水化合物的原药、药物和给药系统，重点介绍了现有抗生素的衍生化、纳米技术的使用以及现有治疗剂的再利用，这些都是抗菌剂开发中最常用的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Chemical Biology 生物-生化与分子生物学

CiteScore

13.30

自引率

1.30%

发文量

113

审稿时长

74 days

期刊介绍： COCHBI (Current Opinion in Chemical Biology) is a systematic review journal designed to offer specialists a unique and educational platform. Its goal is to help professionals stay informed about the growing volume of information in the field of Chemical Biology through systematic reviews.